news
New method to induce target-specific immune responses
By fusing antigen proteins into an anchor protein, a specific disease could be targeted without the need to purify the antigen.
List view / Grid view
Vaccine development
whitepaper
Beyond the lab: RNA
Download this exclusive content focusing on new RNA editing technology, the challenges and opportunities presented and the potential of RNA-based therapeutics.
whitepaper
Beyond the lab: cancer research
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
news
Vaccines against parasitic disease
In Columbus, Ohio, scientists have made significant strides in developing vaccines to combat leishmaniasis, a disfiguring skin disease, through animal studies.
news
Immune cells predict flu symptoms
St. Jude Children’s Research Hospital, in collaboration with ESR Limited, discovered that specific immune cells present in individuals months before a flu infection can better predict symptom development compared to current antibody-based methods.
news
Vaccine may reduce severity of long-haul covid symptoms
Receiving a COVID-19 vaccination could offer a dual benefit by not only lowering the likelihood of developing long-haul COVID but also mitigating symptoms for individuals already dealing with this condition.
article
Advancing vaccine design: potential of peptide mimicry
A new discovery presents a bioinformatic approach for improving vaccine effectiveness against infectious agents such as COVID-19.
news
Novel vaccine key to reduce Alzheimer’s impact
Promising preliminary research reveals a novel vaccine targeting an Alzheimer’s disease-related protein successfully eliminated toxic cells in mice afflicted with the condition.
news
HPV vaccine cost reimbursement could hinder vaccine access
Bare minimum reimbursement rates could be why some clinics may be struggling to offer HPV vaccination in the US.
article
Addressing the grand challenge of global access to vaccines
Tracy Saveria, James Roberts and Brian Finrow from Lumen Bioscience discuss progress in the aspiration for global vaccine access and how Lumen Bioscience’s inhalation malaria vaccine represents a major step towards it.
